Molnupiravir (Esperavir) — Competitive Intelligence Brief

Molnupiravir (Esperavir) (Molnupiravir (Esperavir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Infectious Disease / Virology.

phase 3 Nucleoside analog antiviral Viral RNA-dependent RNA polymerase Infectious Disease / Virology Small molecule

Target snapshot

Molnupiravir (Esperavir) (Molnupiravir (Esperavir)) — Promomed, LLC. Molnupiravir is a nucleoside analog that induces viral mutagenesis by causing errors during viral RNA replication, leading to viral extinction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Molnupiravir (Esperavir) TARGET	Molnupiravir (Esperavir)	Promomed, LLC	phase 3	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase
ribavirin pre-treatment	ribavirin pre-treatment	University of Roma La Sapienza	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
Ribavirin (SCH 018908)	Ribavirin (SCH 018908)	Merck Sharp & Dohme LLC	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; GTP depletion
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Ribavirin (R)	Ribavirin (R)	Tibotec Pharmaceuticals, Ireland	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Ganovo+ritonavir+/-Interferon nebulization	Ganovo+ritonavir+/-Interferon nebulization	The Ninth Hospital of Nanchang	marketed	Antiviral combination therapy	Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog antiviral class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Hoffmann-La Roche · 2 drugs in this class
3. Göteborg University · 2 drugs in this class
4. Estetra · 1 drug in this class
5. Padagis LLC · 1 drug in this class
6. MinaPharm Pharmaceuticals · 1 drug in this class
7. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Ain Shams University · 1 drug in this class